News
AI · Board Appointment · Healthcare · IPO
Artificial intelligence corporation Anthropic appointed Novartis CEO Vasant Narasimhan to its board, accelerating its expansion into healthcare and preparations for an initial public offering (IPO) by leveraging his expertise in public health and medicine.
Anthropic announced the appointment on April 14th (local time), stating its independent Long-Term Benefit Trust (LTBT) named Narasimhan as a new director. Narasimhan, a physician-scientist and member of the U.S. National Academy of Medicine, is expected to significantly strengthen Anthropic's AI applications in healthcare and life sciences.
This strategic move follows Anthropic's recent expansion of partnerships with global drugmakers such as Eli Lilly and Novo Nordisk, alongside increased investment in the sector, including the acquisition of life-science startup Coefficient Bio. The appointment completes the LTBT's structure, which holds authority to appoint and dismiss a majority of directors, ensuring its independent oversight.
The current seven-member board includes founders Dario and Daniela Amodei, investor representatives, and Netflix co-founder Reed Hastings. Anthropic also plans to unveil its next-generation AI model, "Claude Opus 4.7," and an AI-based design tool as early as this week.
